Copanlisib+Rituximab Shows Promise for Some Lymphomas

According to the American Society of Hematology (ASH), findings from phase III of the CHRONOS-3 trial testing a combination therapy using copanlisib and rituximab reduced the risk of progression or death by 48% compared with rituximab alone. The study was open to participants who had relapsed Indolent B-cell Non-Hodgkin’s Lymphoma, including follicular lymphoma, small lymphocytic…… Continue reading Copanlisib+Rituximab Shows Promise for Some Lymphomas

Purdue Study – Undruggable Cancer Protein in the Crosshairs

‘Undruggable’ cancer protein becomes druggable, thanks to shrub by Brittany Steff originally appeared at perdue.edu. WEST LAFAYETTE, Ind. — A chemist from Purdue University has found a way to synthesize a compound to fight a previously “undruggable” cancer protein with benefits across a myriad of cancer types. Inspired by a rare compound found in a…… Continue reading Purdue Study – Undruggable Cancer Protein in the Crosshairs